Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures: 2020-2025

Historic Gains from Sales and Divestitures for Revolution Medicines (RVMD) over the last 5 years, with Sep 2025 value amounting to $978,467.

  • Revolution Medicines' Gains from Sales and Divestitures rose 34.97% to $978,467 in Q3 2025 from the same period last year, while for Sep 2025 it was $978,467, marking a year-over-year increase of 34.97%. This contributed to the annual value of $1.0 million for FY2024, which is 75.27% up from last year.
  • Revolution Medicines' Gains from Sales and Divestitures amounted to $978,467 in Q3 2025, which was up 54.45% from $633,511 recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Gains from Sales and Divestitures registered a high of $1.0 million during Q4 2024, and its lowest value of $1,798 during Q1 2021.
  • Over the past 3 years, Revolution Medicines' median Gains from Sales and Divestitures value was $469,031 (recorded in 2024), while the average stood at $508,824.
  • Data for Revolution Medicines' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 4,540.69% (in 2021) over the last 5 years.
  • Over the past 5 years, Revolution Medicines' Gains from Sales and Divestitures (Quarterly) stood at $78,010 in 2021, then surged by 257.45% to $278,848 in 2022, then surged by 106.91% to $576,974 in 2023, then spiked by 75.27% to $1.0 million in 2024, then skyrocketed by 34.97% to $978,467 in 2025.
  • Its Gains from Sales and Divestitures stands at $978,467 for Q3 2025, versus $633,511 for Q2 2025 and $271,536 for Q1 2025.